With more than 15,000 annual deaths from head and neck cancer (HNC), an important aspect of end-of-life care for these patients is place of death. Recent evidence suggests an increasing preference for home/hospice at end of life; however, it is unclear whether there is variation in home...
Head and neck squamous cell carcinomas (HNSCC) are the fifth most common cancer globally. They emerge in the upper aero-digestive tract (including the oral cavity, pharynx and larynx). HNSCC exhibit high levels of heterogeneity and deep differences in therapeutic response1. Conventional HNSCC class...
BACKGROUNDSurvivors of head and neck squamous cell carcinoma (HNSCC) face excess mortality from multiple causes.METHODSWe used the population-based Surveillance, Epidemiology, and End Results (SEER) cancer registry data to evaluate the causes of death in patients with nonmetastatic HNSCC diagnosed betw...
We briefly highlight the growing body of recent evidence linking unprotected oral sex with the development of some types of head and neck cancer in younger patients. These tumours appear to be increasing in incidence although the development of more sens
- 《International Journal of Cancer Journal International Du Cancer》 被引量: 302发表: 1997年 Analysis of p53 Serum Antibodies in Patients With Head and Neck Squamous Cell Carcinoma We assayed serum samples from 80 patients with head and neck squamous cell carcinoma (HNSCC) for the presence of ...
Methods We retrospectively queried the Surveillance, Epidemiology, and End Results (SEER) 18 database3 from 2000 through 2014 for eligible cases of adults with head and neck squamous cell carcinoma (first or only cancer with known cause of death). Because SEER is a publicly available database ...
locally advanced head and- neck cancer after weekly cisplatin plus concomitant boost accelerated radiation treated in our center.Ninety-four patients with locally advanced head and neck carcinoma were included in this phase II trial consisting of concomitant boost radiation plus concurrent weekly cisplatin...
Head and neck cancer accounts for approximately 3 percent of all cancers in the United States, and over 90% of them are head and neck squamous cell carcinoma (HNSCC). Chemotherapeutic drugs that treat HNSCC can activate BCL-2 family dependent apoptosis. Pro-apoptotic NOXA induced by adenovirus ...
Hypoxia-induced miR-5100 promotes exosome-mediated activation of cancer-associated fibroblasts and metastasis of head and neck squamous cell carcinoma Yuansheng Duan ,Mengqian Zhou &Chao Jing Article 05 March 2024|Open Access Deciphering the tumor immune microenvironment of imatinib-resistance in advanced...
et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450–462 (2021). Article CAS Pub...